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ABSTRACT
The osprey (Pandion haliaetus) is a well‐known sentinel of environmental contamination, yet no studies have traced
pharmaceuticals through the water–fish–osprey food web. A screening‐level exposure assessment was used to evaluate the
bioaccumulation potential of 113 pharmaceuticals andmetabolites, and an artificial sweetener in this foodweb. Hypothetical
concentrations in water reflecting “wastewater effluent dominated” or “dilution dominated” scenarios were combined with
pH‐specific bioconcentration factors (BCFs) to predict uptake in fish. Residues in fish and osprey food intake rate were used to
calculate the daily intake (DI) of compounds by an adult female osprey. Fourteenpharmaceuticals and adrugmetabolitewith a
BCF greater than 100 and a DI greater than 20mg/kg were identified as being most likely to exceed the adult human
therapeutic dose (HTD). These 15 compounds were also evaluated in a 40 day cumulative dose exposure scenario using first‐
order kinetics to account for uptake and elimination. Assuming comparable absorption to humans, the half‐lives (t1/2) for an
adult osprey to reach theHTDwithin 40 dayswere calculated. For 3 of these pharmaceuticals, the estimated t1/2 in ospreys was
less than that for humans, and thus an osprey might theoretically reach or exceed the HTD in 3 to 7 days. To complement the
exposuremodel, 24 compoundswere quantified inwater, fish plasma, and osprey nestling plasma from7potentially impaired
locations in Chesapeake Bay. Of the 18 analytes detected inwater, 8were found in fish plasma, but only 1 in osprey plasma (the
antihypertensive diltiazem). Compared to diltiazem detection rate and concentrations in water (10/12 detects, <method
detection limits [MDL]–173ng/L), there was a lower detection frequency in fish (31/233 detects, <MDL–2400ng/L); however
when present in fish, all values exceeded the maximum diltiazem concentration found in water. Diltiazem was found in all 69
osprey plasma samples (540–8630ng/L), with 41% of these samples exceeding maximum concentrations found in fish.
Diltiazem levels in fish and osprey plasma were below the human therapeutic plasma concentration (30 000ng/L). Effect
thresholds for diltiazem are unknown in ospreys at this time, and there is no evidence to suggest adverse effects. This
screening‐level exposure model can help identify those compounds that warrant further investigation in high‐trophic level
species. Integr Environ Assess Manag 2015;11:118–129. © 2014 SETAC
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INTRODUCTION
In parallel with human population growth and a myriad of
veterinary and human health uses, pharmaceuticals and their
metabolites primarily enter the environment through waste-
water from bulk drug production, sewage plants and septic
systems, and in biosolids applied to agricultural lands (Kolpin
et al. 2002; Ramirez et al. 2009). The development of advanced
analytical techniques and widespread monitoring has revealed
the presence of pharmaceuticals in a variety of environmental
matrices (sediments, sewage sludge, water, and fish). Pharma-
ceuticals may not be completely removed by traditional
wastewater treatment systems, and with constant wastewater
inputs, even labile compounds may exhibit pseudo‐persistence
in surface waters (Daughton and Ternes 1999; Celiz et al.
2009). Their detection in the environment has raised concerns
about bioaccumulation, transfer through the food web, and
potential effects that pharmaceutical “cocktails” may elicit on
ecosystems.
Understanding ecological risks of pharmaceuticals to free‐
ranging wildlife (amphibians, reptiles, birds, and mammals)
remains a major research need (Boxall et al. 2012), the one
exception being the nonsteroidal anti‐inflammatory drug
(NSAID) diclofenac used to treat livestock. Diclofenac use
resulted in nontarget poisoning and endangerment of several
species of Asian vultures feeding on carcasses of cattle that had
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been treated with this drug (Oaks and Watson 2011). The
catastrophic effects of diclofenac on old world vultures resulted
in detailed investigations of several NSAIDs in birds. A recent
workshop evaluated the risk of pharmaceuticals to wildlife and
identifiedmajor information gaps including the need to conduct
food web exposure modeling and environmentally realistic risk
assessments (Arnold et al. 2013). Hernout et al. (2011) also
suggested that prioritizing chemicals (e.g., metals, pesticides,
pharmaceuticals) in a foodweb framework before intensive and
costly investigation would be beneficial to natural resource
managers and policymakers.
Ospreys (Pandion haliaetus) are a high trophic level species
that have served as sentinels of ecosystem health and
environmental change (Grove et al. 2009). Their eggs and
blood are excellent matrices to document spatial and temporal
trends and to elucidate exposure, bioaccumulation, and
biomagnification of contaminants. Ospreys are strictly piscivo-
rous and this aspect makes their diet easy to monitor and link to
sources of localized contaminant exposure. Their diet can vary
with salinity (Glass and Watts 2009), prey availability, and
trophic position and can range from anadromous fish in
polyhaline regions to nonmigratory fish in oligohaline waters.
Ospreys are adaptable to human landscapes and can be found
nesting in highly industrialized and urbanized areas and even in
proximity to wastewater treatment plants (WWTPs).
To date, no studies have examined the bioaccumulation of
pharmaceuticals and their fate in the water‐fish‐osprey food
web. This study describes a framework and the findings of a
screening‐level exposure assessment to estimate the daily and
cumulative 40 day intake of pharmaceuticals that are being
analyzed by some environmental research laboratories (Du
et al. 2012; Furlong et al. 2014). This was complemented by
empirical analyses of 23 compounds and an artificial sweetener
analyzed in water and blood plasma of fish and osprey nestlings
from sites located along potentially impaired waterways in
Chesapeake Bay.
METHODS
Screening‐level exposure model: Daily intake
The daily intake (DI) of 113 pharmaceuticals, metabolites,
and an artificial sweetener (Table S1) by an adult female osprey
was calculated to determine which compounds reached or
exceeded the human therapeutic dose (HTD) (assumes
comparable intestinal absorption for both ospreys and
humans) (Figure 1). These compounds are quantified at the
US Geological Survey National Water Quality Laboratory
(Furlong et al. 2014) and some of these compounds are
analyzed in fish plasma (Du et al. 2012). Three hypothetical
exposure regimes (10, 100, and 1000 ng/L) were chosen
(ranging from “dilution dominated” high flow to “wastewater
effluent dominated” low flow) (Brooks et al. 2006) and
modeled across 3 pH values (pH 6, pH 7, pH 8) that are
representative of surface water gradients at field study sites.
The pH consideration is important, because the drugs
examined are all potentially ionizable and their bioconcentra-
tion factors (BCFs) are pH‐specific and dependent on log D (a
measure taking into account ionized and un‐ionized forms of a
molecule) (Meylan et al. 1999; Fu et al. 2009). These factors
can influence bioaccumulation and toxicity in fish (Valenti
et al. 2009, 2011, 2012), and ultimately, their absorption
(bioaccessibility) in the gastrointestinal tract of birds. Predicted
BCFs for each substance (ACS 2014) were used to calculate
the quantity of a pharmaceutical accumulated in a generic fish
in 24 hours (Berninger et al. 2011).
Calculated pharmaceutical residues in fish from each
scenario were used to estimate the DI for a 1568 g adult female
osprey (USEPA 1993). Due to the complexities in modeling
cumulative exposure of a growing osprey nestling (e.g., logistic
growth plateauing at 40 days, changing food intake, and
metabolic demands, etc.), a 40 day exposure assessment for an
adult osprey was conducted. Food intake rate (FIR) was
estimated 2 ways. The first estimate used osprey bite size and
bodyweight (BWt) to calculate a FIR of 329 g of fishwetweight
(ww) per day (Poole 1985; USEPA 1993). The second estimate
used dry weight (dw) consumption rates based on the
relationship between BWt and metabolic energy for birds
(FIR g dw/day¼ 0.648BWt0.651) (Nagy 1987; USEPA 1993).
The FIR for an adult female osprey (77.94 g fish dw/day)
converted to ww (assuming 75% water content for a generic
fish) was 312 g/day. These 2 estimates yielded similar results
and the metabolic‐based estimate was selected for use. The DI
(mg pharmaceutical/kg Bwt) was calculated using Equation 1
DI ¼ ðresidue in fishÞðFIRÞ=ðkg BWtÞ: ð1Þ
The DIs for varying degrees of absorption were compared to
the oral HTD for an adult. Human therapeutic doses were
obtained as the minimum daily dose to exert a therapeutic
effect (RxList 2008; FDA 2012; Drugsite Trust 2014).
Screening‐level exposure model: 40 day cumulative intake
To estimate cumulative body burden of ospreys, assumptions
included that diet was the principal exposure route, BWt and
FIR were constant, and intestinal absorption was comparable
between ospreys and humans. Clearance was incorporated
assuming a first‐order kinetic elimination equation to calculate
total exposure (i.e., mg/kg BWt) because the majority of
ionizable pharmaceuticals follow this type of elimination
(Bardal et al. 2011). Using DI (t¼ 1 d), exposure (E) oscillated
following a saw‐tooth pattern between peak (Epeak) and trough
(Etrough)
Epeak ¼ ðDIremainingÞekt þDI ðjust after mealÞ; ð2Þ
Etrough ¼ ðDIremainingÞekt þ ðDIÞekt ðjust before a mealÞ;
ð3Þ
t1=2 ¼ lnð2Þ=k ðhalf-life elimination constantÞ: ð4Þ
There are limited data on the half‐lives (t1/2) of pharma-
ceuticals in birds to apply in these equations. To place the
40 day exposure into perspective, the drug t1/2 in ospreys
needed to reach or exceed the HTD within 40 days at most
extreme scenario (1000 ng/L concentration, pH 8, complete
absorption) was back calculated. Equation 3 (daily exposure at
nadir) was used to conservatively estimate cumulative daily
body burden. The back calculated t1/2 for ospreys was
compared to the t1/2 in humans (Ebadi 2008; Wishart
et al. 2008; FDA 2012).
Empirical pharmaceutical exposure data
Study sites were selected in urbanized areas in proximity to
WWTPs, combined sewer outflows, and effluent dominated
low flow sites. These sites include the Susquehanna River (MD,
PA), Back River (MD), James River (VA), and the US
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Environmental Protection Agency (USEPA) designated Re-
gions of Concern (Baltimore Harbor [MD], Anacostia River/
middle Potomac [DC, MD, VA], and the Elizabeth River
[VA]), all of which appear on the 303d list for impaired
waterways (Figure 2) (USEPA 2013). Sampling was undertak-
en during osprey nesting seasons of 2011, 2012, and 2013. The
Paul S. Sarbanes EcosystemRestoration Project at Poplar Island
(MD), a remote mid‐Bay location, was used as a reference site.
Duplicate water samples were collected from 12 select
sampling sites (2–3 locations along a stretch of the Susquehanna
River, Back River, Anacostia/middle Potomac Rivers, James
River, and at Poplar Island). Surface water samples were
collected in clean 4 L amber glass jugs. Field blanks were taken
by opening an empty jar to account for other sources of
contamination. Water quality parameters (pH, dissolved O2,
temperature, conductivity) were measured concurrently (YSI
Multimeter Yellow Springs OH). Water samples were stored
on wet ice and shipped overnight to Baylor University.
All procedures involving fish and ospreys were conducted
under approval of the Institutional Animal Care and Use
Committees of the US Geological Survey (USGS) and the
University of Maryland, and appropriate scientific collection
permits. Game camera (Bushnell 8MP Trophy Cam, Overland
Park, KS) images of prey items delivered to osprey nests, direct
observations, and identification of scraps were used to
reconstruct osprey diet and identify target species for sampling.
Based on osprey diet reconstruction, a combination of gizzard
shad (Dorosoma cepedianum), catfish (blue catfish Ictalurus
furcatus, brown bullhead Ameiurus nebulosus, and channel
catfish Ictalurus punctatus), and carp (Cyprinus carpio) were
sampled on the Susquehanna, Anacostia/middle Potomac, and
James Rivers. Atlantic menhaden (Brevoortia tyrannus), striped
bass (Morone saxatilis), and white perch (Morone americana)
were sampled at the more saline Poplar Island site, and a
combination of carp, catfish, gizzard shad, and white perch
were sampled on Back River. These fish species reflect different
trophic levels ranging from primary consumers (herbivorous)
such as Atlantic menhaden and gizzard shad, to secondary
consumers (carnivorous) including white perch and striped
bass, to catfish and carp (omnivorous) representing a combina-
tion of both primary and secondary consumers. Fish were
captured by electroshocking in upriver sites. At Poplar Island,
Figure 1. Theoretical screening‐level exposure assessment framework used to model the daily intake (DI) for an osprey.
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fish were captured using a midwater trawl and a commercial
pound net. Plasma was sampled from the 2 to 3 dominant prey
fish species found at each site that fell within the osprey foraging
size range (25–35 cm) (Poole 1989). All fish (n¼233) were
anesthetized (MS222, tricane methanesulfonate), weighed,
measured, and 1 to 2 mLs of blood were sampled using a
heparinized syringe. Fish blood was stored on wet ice and
transported to the USGS‐Leetown Science Center in WV. The
blood was centrifuged at 2000 g at 4°C for 10min on the same
day of collection. Plasma was harvested for pharmaceutical
analyses and stored at 80°C. Fish tissue was saved for analysis
of organic contaminants as part of a concurrent study.
Osprey nests were identified in mid‐March along a 25 to
35 km stretch of river. A sample egg was collected for analysis
of legacy contaminants and nests were visited weekly to
determine reproductive success as part of a concurrent study.
Once nestlings reached 40 to 45 days of age, a single chick was
briefly removed from the nest (<10min). Body weight and
culmen length were measured, and a 5 to 7mL brachial blood
sample was drawn into a heparinized syringe. Samples were
stored on wet ice and centrifuged at 1500 g at 4°C for 10min on
the same day of collection. Plasma was harvested and samples
(n¼ 69) were stored at the USGS‐Patuxent Wildlife Research
Center at 80°C. All plasma samples were shipped frozen to
Baylor University for the quantification of pharmaceuticals.
Analysis of pharmaceuticals
A suite of 23 pharmaceuticals and metabolites and an artificial
sweetener (Tables S1 and S2) were quantified in water and
plasma samples fromfish and osprey nestlings via isotopic dilution
liquid chromatography‐tandem mass spectrometry (LC‐MS/
MS). These compounds included analgesics (acetaminophen,
codeine), antibiotics (erythromycin, sulfamethoxazole, trimeth-
oprim), an anticoagulant (warfarin), antidepressants (paroxetine,
Figure 2. Map detailing the locations of Chesapeake Bay study sites.
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fluoxetine, sertraline, and primary metabolites norfluoxetine
and desmethylsertraline), an antihistamine (diphenhydramine),
antihypertensives (atenolol, diltiazem, propranolol), anti‐
inflammatories (celecoxib, diclofenac), an antilipemic (gemfi-
brozil), an antiseizure (carbamazepine), a parasiticide (ivermec-
tin), psychostimulants (diazepam,methylphenidate), a stimulant
(caffeine), and an artificial sweetener (sucralose; conservative
tracer of effluent discharges) (Soh et al. 2011).
For water, sample filtration and extraction generally followed
previously described protocols (Du et al. 2014). A mixture of
24 internal standards (deuterated analogues of target com-
pounds, except for ivermectin for which abamectin was the
internal standard) and 5mL of methanol was added to 500mL
of each water sample before extraction and acidification
(pH adjusted with 100mL of 85% [v/v] phosphoric acid)
(Lajeunesse et al. 2008). Resulting concentrations of internal
standards were approximately 100 ng/g. Samples were subse-
quently loaded onto strong cation‐exchange cartridges (Strata‐
SCX, 500mg; Phenomenex, Torrance, CA) preconditioned
with 4mL of methanol and 8mL of nano‐pure water. Each
cartridge was washed with 4mL of HCl (0.1N) and 4mL of
methanol, followed by elution of the 5 antidepressant serotonin
reuptake inhibitorswith 6mLof 5% (v/v)NH4OH inmethanol.
Extraction of 19 other analytes generally followed a previously
reported protocol (Vanderford and Snyder 2006). Each sample
(500mL subsample) was spiked with a mixture of internal
standards and loaded onto a preconditioned HLB cartridge
(200mg, Waters, Milford, MA). These loaded cartridges were
air‐dried and subsequently eluted with 5mLmethanol followed
by 5mL 10:90 (v/v) methanol‐methyl tertiary butyl ether. The
eluate from 2 separate extractions was evaporated to dryness
under a stream of N and reconstituted in 1mL of chro-
matographic mobile phase (i.e., methanol‐0.1% [v/v] aqueous
formic acid). Before LC‐MS/MS analysis, samples were
sonicated for 1min and filtered using Pall Acrodisc hydrophobic
Teflon Supor membrane syringe filters (13mm diameter;
0.2mm pore size; VWR Scientific, Suwanee, GA).
For plasma samples, a slightly modified extraction method
was used (Fick, Lindberg, Parkkonen et al. 2010). An aliquot of
fish and osprey plasma (typically 1mL), combined with the
samemixture of internal standards that was used for water, was
diluted to 5mL using 0.1% (v/v) aqueous formic acid and
mixed thoroughly by sonication. The mixture was loaded on
preconditioned (5mL of methanol and 5mL of nano‐pure
water) HLB SPE cartridges (200mg, Waters). Each cartridge
was air‐dried and subsequently eluted with 5mL of methanol.
The eluate was reconstituted, and analytes were quantified by
LC‐MS/MS as previously described (Du et al. 2012).
For water and fish plasma, method detection limits (MDLs)
were less than 11ng/L with the exception of ivermectin and
sucralose (Table S2). Osprey plasma from the reference site,
spiked with the mixture of internal standards, was used to
determine MDLs, which were similar to that of water and fish
(Table S2). For quality control purposes, 1 pair of matrix spike
samples and 1 method blank sample was added for each batch
analysis. Spike recoveries ranged from 81% to 111% in water,
81% to 113% in fish, and 81% to 89% in ospreys.
Statistical analyses
For the daily and 40 day screening‐level exposure models, DI
and half‐life elimination constants were estimated using
Microsoft Excel. For empirical exposure data, concentrations
of pharmaceuticals and an artificial sweetener were first
recovery corrected and only values above the MDL were
reported. If the analyte was present in all samples, the
arithmetic mean and standard deviation were obtained using
SAS (SAS Institute, NC). If an analyte was detected in only 1 of
the 2 duplicate water samples, one randomly selected value was
included in the statistical analysis. If analytes were detected in
over half (but not all) of the samples at a study location, the
Kaplan‐Meier method was used to estimate an interval that
contains the theoretical mean (Helsel 2005, 2009).
Parametric statisticswere conducted for those analytes detected
in all samples. Continuously distributed analyte concentrations in
water, and fish and osprey plasma were tested for homogeneity of
variance (Levene’s test) and normality (Shapiro‐Wilk test). In 2
instances, variables were log or square root transformed to correct
for normality or heterogeneous variances. A 1‐way analysis of
variance followed by Tukey’s honestly significant difference
method for multiple comparisons was performed (a¼ 0.05). For
those sites with nondetects, a generalizedWilcoxon nonparamet-
ric test was used (Helsel 2005).
For all detectable compounds, a hazard quotient (HQ) was
calculated by dividing the maximum concentration found in
fish or osprey plasma by the human therapeutic plasma
concentration (Cmax). The larger the HQ value, the greater
the potential for a compound to exert a pharmacological effect
in fish or ospreys.
RESULTS
Screening‐level exposure model
Of 114 compounds, 31 had a BCF less than or equal to 1.00
(Table S1). These 31 compounds plus the bronchodilator
tiotropium (no BCF available) were excluded from the model.
Of the 83 remaining compounds, 15 had both a BCF greater
than 100 and an estimatedDI greater than 20mg/kg‐day and are
predicted to have the greatest potential to bioaccumulate. The
calculated DIs for these 15 compounds at concentrations of 10,
100, and 1000 ng/L in an adult female osprey are presented in
Table 1. At concentrations of 1000 ng/L water at pH 8, the DI
of orlistat, fenofibrate, tamoxifen, and loperamide would be 1.1
to 4.4 times greater than the oral HTD. Based on the
information in Table 1, orlistat is the only compound that still
exceeds the HTD even if the intestinal absorption in ospreys
was only half that of humans (12 198mg/kg BWt‐day, 2.4 times
greater than theHTD). Pharmaceutical concentrations inwater
and pH values selected in the model were environmentally
realistic (analyte concentrations in Chesapeake Bay range from
0.029 to 10249 ng/L and site pH ranged from 6.15 to 8.34)
(Tables 3 and S3).
Cumulative 40 day exposure model
For the top 15 compounds (BCF> 100, DI>20mg/kg
BWt‐day), the theoretical half‐life (calculated from the
half‐life elimination constant, k) for an osprey to reach the
HTDwithin a 40 day period ranged from 1 to 231 days. For this
subset of pharmaceuticals, the half‐lives in humans ranged from
0.04 to 7 days. Notably, the half‐lives in ospreys for fenofibrate,
tamoxifen and ezetimibe were less than that in humans, with
the HTD being exceeded in just 3 to 7 days (Table 1).
Empirical assessment of pharmaceuticals in water, fish,
and osprey
Of the 24 analytesmeasured, 17were detected inwater and 8
of these were also detected in fish (Tables 2, S3, and S4).
122 Integr Environ Assess Manag 11, 2015—RS Lazarus et al.
Diltiazem was the only compound detected in all 3 matrices
(Table 3, all values presented on a ng/L basis). When compared
to the human therapeutic plasma concentration (Cmax), all
detected compounds had a HQ less than or equal to 0.08.
In water, concentrations were averaged from the 2 to 3
sampling sites per tributary. There were 73 out of 77 instances
where the analyte was detected in the duplicate water samples
and the median relative percent difference between samples
was 12.02%. Samples were collected from the reference site
each year of the study, but diltiazemwas only detected in water
samples in 2011 and 2012. At Back River, 18 analytes were
detected in water with concentrations being 2 to 154 times
greater than other sites. Carbamazepine, diltiazem, sulfameth-
oxazole, diphenhydramine, and caffeine were detected in water
at all intensively sampled sites. Statistical analysis revealed that
the Anacostia/middle Potomac Rivers had the greatest
carbamazepine (log transformed) and caffeine concentrations
in water (Back River excluded from analysis as there was only a
single sample), followed by the James, Poplar Island, and
Susquehanna (p< 0.04). There were no differences in diltia-
zem concentrations in water among all 5 sites.
Although 7 pharmaceuticals and sucralosewere found in fish,
detection frequency was low, rarely exceeding half of the
samples per site. Thus, parametric statistical analyses could not
be conducted among analytes, fish species, and sites (Table S4).
By inspection of these data, diphenhydramine and diltiazem
were present in fish from all study sites. Both the Anacostia/
middle Potomac and Back Rivers had the largest suite of
pharmaceuticals detected. Diltiazem was found in 13% of fish
samples and present in all species, with the greatest plasma
concentration (2.4 ng/mL) found in a catfish collected on the
Susquehanna (Table 3).
Diltiazem was detected in all 69 osprey nestling plasma
samples (1.6–24.6 times greater than the MDL). Osprey
nestlings on the Anacostia/middle Potomac, Baltimore Harbor,
and Back River had higher (p< 0.04) diltiazem plasma
concentrations (square root transformed) compared to the
James, Elizabeth, Susquehanna Rivers, and the Poplar Island
reference site. Plasma diltiazem concentrations at Poplar were
higher than those on the Elizabeth and James Rivers
(p< 0.007). For the Potomac River, which had osprey nests
evenly spaced downriver from Blue PlainsWWTP, diltiazem in
nestling plasma did not exhibit a spatial concentration gradient
(p> 0.35).
DISCUSSION
Screening‐level exposure assessment
Whereas several studies have examined uptake of pharma-
ceuticals from water by fish (Brown et al. 2007; Ramirez
et al. 2009), their transfer to high trophic level wildlife has not
been evaluated. The likelihood for a broad suite of potentially
ionizable pharmaceuticals to bioaccumulate in a water–fish–
osprey food web was modeled using their concentration in
Table 1. DI at 3 water concentrations and t1/2 to accumulate an HTD within 40 days for 15 pharmaceuticals compared to human values
Rank Compound BCF pH 8
DI osprey (100% absorption)
(mg/kg BWt‐day)a
HTD (mg/kg BW)
t1/2 ospreys to exceed
HTD 100% absorptiona
t1/2 humans (d)
10ng/L 100ng/L 1000ng/L 1000ng/L
pH 8 pH 8 pH 8 pH 8
1 Orlistat 123 000 244 2440 24 396a 5143 1.79 0.04–0.08
2 Fenofibrate 15 100 29.9 299 2995a 1714 0.42a (HTD in 3 d) 0.83
3 Piperonyl butoxide 2400 4.76 47.6 476 Topical NAb NA
4 Tamoxifen 797 1.58 15.8 158a 143 1.00a (HTD in 4 d) 5–7
5 Ketoconazole 646 1.28 12.8 128 2857 22.8 0.14
6 Ezetimibe 589 1.16 11.6 117 143 1.19a (HTD in 7 d) 0.79–1.25
7 Iminostilbeneb 556 1.10 11.0 110 5714 34.3 0.08–2.71
8 Loratadine 538 1.06 10.7 107 143 1.27 0.35
9 Loperamide 519 1.03 10.3 103a 57.1 0.67 0.45
10 Promethazine 358 0.71 7.10 71.1 357 4.07 0.67–0.79
11 Diltiazem 343 0.68 6.80 68.0 2571 231 0.12–0.18
12 Raloxifene 327 0.65 6.50 65.0 857 11.3 1.15
13 Dextromethorphan 228 0.45 4.52 45.2 571 11.3 0.05–0.16
14 Desmethylsertraline 213 0.42 4.20 42.3 NA NA 2.58–4.33
15 Sertraline 142 0.28 2.82 28.2 357 11.5 1.04–1.08
DI¼daily intake; HTD¼human therapeutic dose; NA¼not applicable; not ingested for therapeutic uses or a metabolite of a parent compound.
aIndicate the estimated DI or t1/2 for ospreys exceeds HTD or human t1/2.
bIminostilbenes are a group of antiseizure drugs that includes carbamazepine and oxcarbamazepine. HTD and half‐lives are given based on the lowest dose in this
group that is needed for a therapeutic effect.
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Table 2. Summary of compounds detected in water and fish across study sitesa
Site/class
Analgesic Antibiotic Anticoagulant Antihistamine Psychostimulant
Acetaminophen Codeine Sulfamethoxazole Trimethoprim Erythromycin Warfarin Diphenhydramine Methylphenidate Diazepam
Poplar Island
Water þ þ
Atlantic menhaden
Striped bass þ
White perch þ
Anacosita/middle Potomac Rivers
Water þ þ þ þ þ þ
Catfish sp. þ
Gizzard shad þ
Carp þ
Back River
Water þ þ þ þ þ þ þ þ þ
Catfish sp. þ
Gizzard shad þ þ
Carp þ
White perch þ
James River
Water þ þ þ
Catfish sp. þ
Gizzard shad þ
Susquehanna River
Water þ þ
Catfish sp.
Gizzard shad
Antihypertensive Anti‐inflammatories Antilipemic Antiseizure Artificial Sweetener Stimulant
Atenolol Diltiazem Propanolol Celecoxib Diclofenac Gemfibrozil Carbamazepine Sucralose Caffeine
Poplar Island
Water þ þ þ þ
Atlantic menhaden þ
Striped bass þ þ
White perch þ
Anacosita/Middle Potomac Rivers
Water þ þ þ þ þ þ þ
Catfish sp. þ
Gizzard shad þ þ þ
Carp þ
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water, pH‐specific BCF and FIR of an adult female osprey.
Those compounds with high pH‐specific BCFs and long half‐
lives near low flow point sources (i.e., low dilution scenario)
were predicted to exceed the HTD.
This screening‐level assessment identified a subset of 15 of
114 compounds that warrant further investigation based on
their potential to exceed the HTD. Over a narrow range of pH
(6–8), there was little effect on the BCF of 6 of these
compounds (orlistat, fenofibrate, piperonyl butoxide, ezeti-
mibe, iminostilbene, and loratadine), with BCFs fluctuating by
less than 20% (Table S1). Although ionizable at pH extremes
(low or high pKa), these 6 compounds were in their neutral
state from pH 6–8 and predicted to be the most bioaccumu-
lative. It has been suggested that compounds with such
characteristics could evoke pharmacological responses and
possibly toxicity in invertebrates and fish at their isoelectric
point (Ebadi 2008; Rendal et al. 2011). The remaining 10
compounds (mean pKa 8.37) are not ionizable until pH
exceeds environmentally relevant conditions. The use of pH‐
specific BCFs appears to be a valuable tool to identify and
prioritize pharmaceuticals and metabolites that have the
greatest potential to bioaccumulate at environmentally relevant
conditions.
An estimate of the half‐life is required to model first‐order
kinetic elimination of drugs over a specific period of time and
provides a measure of the persistence of a xenobiotic. Based on
our screening‐level exposure model, HTDs for fenofibrate,
tamoxifen, and ezetimibe were exceeded in adult ospreys at
theoretical half‐lives (0.24–1.19 days) that were less than their
half‐lives in humans (0.83–1.25 days) (Ebadi 2008; Wishart
et al. 2008). Such theoretical half‐lives are not unreasonable.
For the aforementioned compounds, it might be possible for an
osprey to accumulate a HTDwithin 3 to 7 days of exposure in a
low‐flow scenario.
Uncertainty factors and model assumptions
There are a suite of model assumptions and sources of
uncertainty that influence DI. This model only takes into
account dietary exposure, which is generally acknowledged to
be the principal exposure route in fish‐eating birds
(USEPA 1993), and that the ingested compounds are absorbed
at a rate comparable to that of humans. Although this
assessment assumed a constant body weight and FIR, this is
unlikely because of variations in prey availability, tidal
influences, and movement of fish in relation to point source,
osprey foraging success, and sibling competition. Environmen-
tal factors, including weather and duration and intensity of
sunlight (UV and visible), can affect the compound before it
enters the prey and its disposition in both prey and predator.
There are a series of factors that must be considered in
extrapolating uptake (i.e., total tissue and plasma concen-
trations) and effect thresholds among species within a
vertebrate class (body weight and surface area [Davidson
et al. 1986], biochemical, genetic, physiological, and behavioral
factors [Dorrestein and Van Miert 1988; Toutain et al. 2010])
and are even more tenuous among classes.
Interspecific differences in drug absorption, distribution,
metabolism, and elimination can be used to place species
sensitivities into perspective. Once a compound is ingested, it is
subject to pH changes in the gut and intestines that can
influence a drug’s ionizable state. Although our model
accounted for environmentally relevant water pH and used
pH‐specific BCFs, it did not include the effects of digestive
tract pH. Of the compounds with the greatest potential for
Table 2. (Continued)
Antihypertensive Anti‐inflammatories Antilipemic Antiseizure Artificial Sweetener Stimulant
Atenolol Diltiazem Propanolol Celecoxib Diclofenac Gemfibrozil Carbamazepine Sucralose Caffeine
Back River
Water þ þ þ þ þ þ þ þ þ
Catfish sp. þ
Gizzard shad þ þ
Carp þ
White perch
James River
Water þ þ þ þ þ þ
Catfish sp. þ þ
Gizzard shad þ
Susquehanna River
Water þ þ þ
Catfish sp. þ
Gizzard shad
aþCompound detected.
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Table 3. Diltiazem concentrations in water, fish, and osprey on ng/L basis
Site
Water (ng/L)
Detects/n
MeanSD
Extremes
Fish (ng/L plasma) Detects/n MeanSD Extremes HQb Osprey
(ng/L plasma)
Detects/n
MeanSDa
Extremes HQbCatfish
Gizzard
shad Carp Rockfish Menhaden Perch
Poplar Island 2/3 NS NS NS 3/17 1/10 1/10 13/13
1.06–1.14c — — — 21991524C
<MDL–2.05 <MDL–1800 <MDL–410 <MDL–410 605–4458
0.06 0.01 0.01 0.15
Anacosita/middle
Potomac Rivers
2/3 0/30 3/33 1/18 NS NS NS 13/13
1.08–1.62c — — — 45171384A
<MDL–2.47 — <MDL–410 <MDL–330 NS NS NS 3503–8630
0.01 0.01 0.29
Back River 1/1 1/2 1/9 0/9 NS NS 0/5 7/7
— — — — — 23531207B,C
173 <MDL–350 <MDL–420 — — 1049–4288
0.01 0.01 0.29
James River 3/3 8/27 3/27 NS NS NS NS 12/12
5.852.51 — — 912225D
2.96–7.49 <MDL–770 <MDL–570 537–1355
0.03 0.02 0.05
Susquehanna River 2/2 9/18 0/18 NS NS NS NS 10/10
1.670.45 — — 1434372C,D
1.35–1.99 <MDL–2400 – 4049–2099
0.08 0.07
Additional sites where
only osprey nestlings
sampled
Elizabeth River 6/6
966352D
564–1320
0.04
Baltimore Harbor/
Patapsco River
8/8
3786714A,B
2885–5110
0.17
—¼ indicates nomean calculated, contaminant was detected in fewer than half of the samples; HQ¼hazard quotient; MDL¼method detection limit; NS¼not
sampled because fish species was not a large component of osprey diet at a particular site; SD¼ standard deviation;
aMeans with different captial letter superscripts are significantly different (p<0.05).
bHQ is the upper extreme concentration found in fish or osprey plasma divided by the human therapeutic plasma concentration (Cmax) for diltiazem (30 000ng/L).
cIf nondetectswere present in<50%of the samples, the Kaplan‐Meiermethodwas used to estimate the extremes of themean followed by a generalizedWilcoxin
nonparametric test.
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bioaccumulation (Table 1), 9 have a pKa greater than 7.5 and 2
have a pKa less than 6.9, thus remaining in their neutral state in
the small intestine favoring increased bioaccessibility. A great
deal is known about metal bioaccessibility in birds (Martinez‐
Haro 2009), but far less is known about the absorption
efficiency and potential interspecific differences of pharma-
ceuticals and many other organic compounds in the avian
gastrointestinal tract. Additional information is required before
bioaccessibility can be included in the model.
Pharmaceuticals have much shorter environmental half‐lives
than persistent organic pollutants, although studies suggest
some pharmaceuticals can exhibit pseudo‐persistence under
effluent dominated scenarios (Daughton 2002; Brooks
et al. 2006). Furthermore, some pharmaceuticals may be
poorly metabolized by fish, resulting in increased potential for
bioaccumulation (Connors et al. 2013). Unlike mammals,
pharmacokinetic parameters (including t1/2) have been esti-
mated for only a few classes of drugs used in disease prevention
and treatment (e.g., antibiotics, antifungals, antivirals, analge-
sics, parasiticides, and sedatives) in a limited number of avian
species (domestic poultry and waterfowl and companion
animals including psittacines) (Goetting et al. 2011;
Guzman 2014). However, for free‐ranging avian wildlife,
pharmacokinetic parameters are unknown, with the exception
of NSAIDs. Notably, diclofenac half‐lives vary by over an order
of magnitude among old world vultures (Accipitridae), new
world vultures (Cathartidae), and domestic poultry (Galli-
formes), and other NSAIDs exhibit a wide range of half‐lives
among orders of birds (Baert and Backer 2003; Naidoo
et al. 2008, 2009). Once a xenobiotic enters the body,
cytochrome P450s are the primary system used to metabolize
foreign compounds (phase I metabolism) with monooxygenase
activity varying across species, sex, age, diet (feeding guild),
season, and disease (Walker 1980). Notably, low monooxyge-
nase activity is found in fish‐eating birds (Walker 1980; Toutain
et al. 2010).
Empirical findings in water and fish
Eighteen pharmaceuticals and an artificial sweetener were
detected in water samples from Chesapeake Bay. Frequency of
detection and concentrations were greatest in water samples
collected on the Back River, which receives appreciableWWTP
input (180 million gallons/day from 1.3 million residents from
Baltimore) (Baltimore County Watershed Management
Program 2012). Despite greater input from Blue Plains
WWTP and population size (330 million gallons/day from
2.1 million residents of the Washington District of Columbia
metropolitan area) (District of Columbia Water and Sewage
Authority 2014), concentrations were seemingly lower on the
Anacostia/middle Potomac Rivers.
Sulfamethoxazole, diphenhydramine, diltiazem, carbamaz-
epine, sucralose, and caffeine were frequently detected in
water samples, and 3 of these (diphenhydramine, diltiazem,
and carbamazepine) were often detected in fish plasma (Tables
S3 and S4). In fish, detection frequency, concentrations, and
HQs were low and far less than critical environmental
concentrations hypothesized to cause pharmacological effects
in fish (Schwab et al. 2005; Fick, Lindberg, Tysklind
et al. 2010; Du et al. 2014). This is not unexpected as other
reports indicate that both sucralose and caffeine do not
bioaccumulate in fish. Sucralose was detected at lower
concentrations in fish than in water samples from the
Anacostia/middle Potomac Rivers and did not bioconcentrate
(maximum detected concentration in fish/maximum detected
concentration in water¼ 0.50; Tables S3 and S4). Notably
laboratory studies have reported a BCF less than 1 for sucralose
in zebrafish (Danio rerio) (Lillicrap et al. 2011) and is not that
different from literature estimates (BCF¼1, Table S1)
(ACS 2014). Of the compounds most frequently detected in
fish, our estimated BCFs were within an order of magnitude
compared to literature values presented in Table S1 (diphen-
hydramine: estimated 79.1 compared with literature value of
16.7; carbamazepine: 44.1 versus 16.2; diltiazem: 319 versus
343). Interestingly, antidepressants were not found in the
present study despite being detected in many urban rivers in
North America (Brooks et al. 2005; Ramirez et al. 2009;
Lajeunesse et al. 2011; Schultz et al. 2010).
Diltiazem was the only analyte detected in water, fish, and
biota. For diltiazem, concentrations in water were low (mean
2.44 ng/L), and with the exception of Back River (173 ng/L),
was generally an order ofmagnitude below those found in urban
inland waters of the United States and Sweden (36–1800ng/L)
(Kolpin et al. 2002, 2004; Fick, Lindberg, Parkkonen
et al. 2010; Du et al. 2014). In Chesapeake Bay, diltiazem
fish plasma concentrations were 2 times greater than those
observed at 3 WWTPs in Sweden (MDL‐1000ng/L) (Fick,
Lindberg, Parkkonen et al. 2010). Out of 10 commonly
used pharmaceuticals tested in Daphnia magna and
Japanese medaka (Oryzias latipes), diltiazem exhibited the
greatest acute toxicity (96h LC50¼ 8.2 and 15.0mg/L,
respectively) (Kim et al. 2007). The predicted no‐effect
concentration for diltiazem based on the lowest acute EC50
values was estimated to be 8.2mg/L (Kim et al. 2007), which is
over an order of magnitude greater than the maximum value
observed in the Back River. Evaluating these data in a more
complete assessment should also include chronic responses
linked to therapeutic hazard (Brausch et al. 2012; Valenti
et al. 2012). The aquatic hazards and risk of diltiazem and
many other pharmaceuticals remain poorly characterized
(Brooks 2014).
Several interspecific differences in pharmaceutical bioaccu-
mulation were found among fish species (Table S4). For
example, diltiazem was detected in channel catfish, but not
gizzard shad from the Susquehanna River, whereas carbamaz-
epine was observed in blue and channel catfish, but again not
gizzard shad from the Anacostia/middle Potomac Rivers.
Spatial variations in fish migration patterns may explain such
differences in pharmaceutical bioaccumulation. For example,
anadromous gizzard shadmigrate downstream to deeperwaters
in the winter, whereas catfish remain in upper estuarine sites
where they may be continuously exposed to wastewater
discharge. The influence of trophic position (e.g., herbivorous
gizzard shad and omnivorous catfish) on pharmaceutical
bioaccumulation in fish is not well understood.
Empirical findings in osprey nestlings
This screening‐level exposure assessment suggests that only 3
of 24 analytes quantified in osprey plasma (diltiazem, sertraline,
and desmethylsertraline) are likely to exceed the HTD. Of
these 3, diltiazem has the highest pH‐specific BCF (343 at pH
8) and was detected in all osprey nestling plasma at low
concentrations (0.56–8.63 ng/mL plasma), with the maximum
value being 28% of the HTD. Although present in all osprey
samples, there were no overt signs (therapeutic or toxicologi-
cal) observed in our companion study examining reproductive
success. Ospreys are thriving in Chesapeake Bay, including the
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most contaminated sites, and reproduction is generally
adequate to sustain stable populations (>1.15 fledglings per
active nest) (Lazarus et al. 2012).
Of the 15 compounds identified in the screening‐levelmodel
as having the greatest potential to bioaccumulate, 3 were
measured in osprey plasma (Table 1; diltiazem 11, desme-
thylsertraline 14, and sertraline 15), and only diltiazem was
detected. The accumulation of diltiazem and other antide-
pressants is theoretically pH‐dependent. The bioaccumulation
characteristics (partition coefficients log p and logD at pH 8) of
sertraline (log p¼ 5.08 and log D¼ 3.60) and its metabolite
desmethylsertraline (log p¼4.89 and log D¼3.73), are not
unlike diltiazem (i.e., log p¼ 4.73 and log D¼ 3.90). Thus,
diltiazem may be bioaccumulating not only because of its high
pH‐specific BCF, but also because of other biological
characteristics including specific binding mechanisms. It is
clear that diltiazem concentrations were greatest in osprey
nestlings followed by fish and water concentrations. Across
sites, the maximum diltiazem concentrations in water, fish
plasma, and osprey plasma were averaged for each matrix to
approximate a biomagnification factor. Diltiazem concentra-
tions in fish plasmawere 21.6 times greater than those inwater,
and osprey plasma concentrations were 4.71 times greater
than fish. It should be noted that the biomagnification factor
from fish to osprey most certainly varies with osprey diet
composition.
CONCLUSIONS
This screening‐level exposure assessment identified 15 out
of 113 pharmaceuticals and an artificial sweetener that warrant
further investigation in fish‐eating birds due to their high BCF
and DI. Some of these compounds might even exceed the
HTD. The antihypertensive drug diltiazem was detected in all
osprey nestling plasma samples in several tributaries of
Chesapeake Bay. Twelve additional analytes that were
predicted to bioaccumulate, but not measured in environmen-
tal samples should receive priority for further investigation.
Although diltiazem in ospreys did not exceed the HTD and
was well below the Cmax, our findings indicate that it can
bioaccumulate to levels that are over 4 times greater than
values in fish plasma. Even though empirical concentrations of
drugs in the present study are well‐below therapeutic levels for
humans, the paucity of effect threshold data for birds and lower
vertebrates makes interpretation of these observations chal-
lenging. Our knowledge of mammalian pharmacology can
assist in extrapolation of effects to wildlife (Huggett
et al. 2003), but in some (and hopefully rare) instances, birds
and other perhaps other classes of vertebrates may be sensitive
to low‐level environmental exposures (Oaks and Watson
2011).
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